[go: up one dir, main page]

MX2018000451A - Composiciones de plinabulina. - Google Patents

Composiciones de plinabulina.

Info

Publication number
MX2018000451A
MX2018000451A MX2018000451A MX2018000451A MX2018000451A MX 2018000451 A MX2018000451 A MX 2018000451A MX 2018000451 A MX2018000451 A MX 2018000451A MX 2018000451 A MX2018000451 A MX 2018000451A MX 2018000451 A MX2018000451 A MX 2018000451A
Authority
MX
Mexico
Prior art keywords
plinabulin
compositions
plinabulin compositions
monohydrated
polymorphs
Prior art date
Application number
MX2018000451A
Other languages
English (en)
Other versions
MX376122B (es
Inventor
Huang Lan
Singh Aniruddh
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57757489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018000451(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2018000451A publication Critical patent/MX2018000451A/es
Publication of MX376122B publication Critical patent/MX376122B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D2009/0086—Processes or apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen en la presente polimorfos de plinabulina, composiciones, su uso y preparación como agentes terapéuticos. En particular, algunas modalidades se relacionan con plinabulina monohidratada en una forma cristalina.
MX2018000451A 2015-07-13 2016-07-11 Composiciones de plinabulina. MX376122B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562191990P 2015-07-13 2015-07-13
PCT/US2016/041773 WO2017011399A1 (en) 2015-07-13 2016-07-11 Plinabulin compositions

Publications (2)

Publication Number Publication Date
MX2018000451A true MX2018000451A (es) 2018-05-07
MX376122B MX376122B (es) 2025-03-07

Family

ID=57757489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000451A MX376122B (es) 2015-07-13 2016-07-11 Composiciones de plinabulina.

Country Status (22)

Country Link
US (5) US10155748B2 (es)
EP (2) EP3334726B1 (es)
JP (2) JP6969848B2 (es)
KR (1) KR102680823B1 (es)
CN (3) CN109516981B (es)
AU (2) AU2016291708B2 (es)
BR (1) BR112018000229A2 (es)
CA (1) CA2991059C (es)
CL (1) CL2018000098A1 (es)
CO (1) CO2018000350A2 (es)
DK (1) DK3334726T3 (es)
EC (1) ECSP18010481A (es)
ES (1) ES2910035T3 (es)
HK (1) HK1251559A1 (es)
IL (1) IL256559B2 (es)
MX (1) MX376122B (es)
MY (1) MY181892A (es)
NZ (1) NZ778077A (es)
PE (1) PE20180528A1 (es)
PH (1) PH12018500071A1 (es)
SG (1) SG10202108194XA (es)
WO (1) WO2017011399A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
HK1250008A1 (zh) 2015-03-06 2018-11-23 万春药业公司 治療與ras突變相關的癌症的方法
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
WO2018028420A1 (zh) * 2016-08-12 2018-02-15 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备纯化方法和应用
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
EP3661927A1 (en) 2017-08-03 2020-06-10 Pliva Hrvatska D.O.O. Salts and solid state forms of plinabulin
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
MX2024009821A (es) * 2022-02-10 2024-09-18 Beyondspring Pharmaceuticals Inc Formulaciones estables de plinabulina y metodos para su preparacion y uso.
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (es) 1973-05-11 1975-01-30
IT1193786B (it) 1980-12-18 1988-08-24 Wellcome Found Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
EP0678298A3 (en) 1992-10-01 1996-05-29 Wellcome Found Use of 4- (2-formyl-3-hydroxyphenoxymethyl) benzoic acid as an immunopotentiating agent.
ES2119996T3 (es) 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
AU747987B2 (en) 1998-01-29 2002-05-30 Aventis Pharmaceuticals Inc. Method for preparing an N-((aliphatic or aromatic)carbonyl)-2-aminoacetamide compound and a cyclyzed compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
HUP0202882A2 (en) 1999-08-23 2002-12-28 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
BRPI0017067B8 (pt) 2000-01-18 2021-05-25 Beyondspring Pharmaceuticals Inc inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
JP2003528068A (ja) 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
BR0110745A (pt) 2000-05-09 2003-12-30 Adpharma Inc Compostos de piperazinadiona
JP2004518731A (ja) 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 三環式ｃｒｆレセプターアンタゴニスト
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
AU2003244646B2 (en) 2002-05-17 2008-08-07 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN101633655B (zh) * 2002-08-02 2014-04-30 大连万春药业有限公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP4616649B2 (ja) * 2002-08-02 2011-01-19 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチンおよびそれらの類似体、ならびにデヒドロフェニラヒスチンおよびそれらの類似体の合成
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1711487A1 (en) 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN1934101B (zh) * 2004-02-04 2011-10-12 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
US7999106B2 (en) 2004-04-19 2011-08-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form I
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
JP4559240B2 (ja) 2005-01-13 2010-10-06 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、無線基地局、無線回線制御局及び電力制御方法
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN103736086A (zh) 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
WO2008128169A1 (en) 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2962731A1 (en) 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EA201190079A1 (ru) 2009-01-16 2013-02-28 Тева Фармасьютикал Индастриз, Лтд. Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011019630A2 (en) 2009-08-10 2011-02-17 Board Of Regents, The University Of Texas System Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
CN102666533A (zh) 2009-09-15 2012-09-12 天蓝制药公司 癌症治疗
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2011109625A1 (en) 2010-03-03 2011-09-09 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2012074904A2 (en) 2010-11-29 2012-06-07 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
SMT201800294T1 (it) 2011-04-20 2018-07-17 Medimmune Llc Anticorpi e altre molecole che legano b7-h1 e pd-1
CA2857191A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
PL2846809T3 (pl) 2012-05-09 2021-07-26 Cantex Pharmaceuticals, Inc. Leczenie mielosupresji
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
BR112015028326A8 (pt) 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
NZ719049A (en) * 2013-10-11 2020-06-26 Beyondspring Inc Cancer treatment with combination of plinabulin and taxane
AU2014346852A1 (en) 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
KR102357699B1 (ko) 2013-11-06 2022-02-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
EP3256130A4 (en) 2015-02-12 2018-08-01 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
HK1250008A1 (zh) 2015-03-06 2018-11-23 万春药业公司 治療與ras突變相關的癌症的方法
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
WO2017062505A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
WO2018169887A1 (en) 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
BR112020015758A2 (pt) 2018-02-01 2020-12-08 Beyondspring Pharmaceuticals, Inc. Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf
MX2020012799A (es) 2018-06-01 2021-03-25 Beyondspring Pharmaceuticals Inc Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
AU2019320830A1 (en) 2018-08-16 2021-02-25 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response

Also Published As

Publication number Publication date
CA2991059C (en) 2024-01-16
PH12018500071B1 (en) 2018-07-23
ES2910035T3 (es) 2022-05-11
DK3334726T3 (da) 2022-05-16
AU2016291708B2 (en) 2020-12-24
AU2021201784B2 (en) 2022-12-01
WO2017011399A1 (en) 2017-01-19
ECSP18010481A (es) 2018-04-30
US20200277280A1 (en) 2020-09-03
NZ778077A (en) 2024-11-29
AU2016291708A1 (en) 2018-02-01
MY181892A (en) 2021-01-12
US12024501B2 (en) 2024-07-02
IL256559B1 (en) 2023-03-01
US20240425485A1 (en) 2024-12-26
KR102680823B1 (ko) 2024-07-03
PH12018500071A1 (en) 2018-07-23
KR20180027563A (ko) 2018-03-14
US10550104B2 (en) 2020-02-04
MX376122B (es) 2025-03-07
US20190106410A1 (en) 2019-04-11
CN108026075B (zh) 2021-06-29
EP3334726A1 (en) 2018-06-20
US20220169635A1 (en) 2022-06-02
SG10202108194XA (en) 2021-09-29
CN113735834A (zh) 2021-12-03
CN113735834B (zh) 2023-06-13
CN108026075A (zh) 2018-05-11
CO2018000350A2 (es) 2018-06-12
BR112018000229A2 (pt) 2018-09-04
CL2018000098A1 (es) 2018-07-20
JP2021181497A (ja) 2021-11-25
EP3334726B1 (en) 2022-03-16
IL256559A (en) 2018-02-28
US11254657B2 (en) 2022-02-22
CA2991059A1 (en) 2017-01-19
US20180194749A1 (en) 2018-07-12
CN109516981B (zh) 2019-10-22
HK1251559A1 (zh) 2019-02-01
EP4011878A1 (en) 2022-06-15
CN109516981A (zh) 2019-03-26
US10155748B2 (en) 2018-12-18
EP3334726A4 (en) 2019-04-17
JP2018520178A (ja) 2018-07-26
PE20180528A1 (es) 2018-03-19
NZ739083A (en) 2024-11-29
JP6969848B2 (ja) 2021-11-24
IL256559B2 (en) 2023-07-01
AU2021201784A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
MX2018000451A (es) Composiciones de plinabulina.
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
DK3360558T3 (da) Sammensætninger omfattende bakteriestammer
DK3369425T3 (da) Sammensætninger omfattende bakteriestammer
DK3650033T3 (da) Sammensætninger omfattende bakteriestammer
DK3377082T3 (da) Sammensætninger, der omfatter bakteriestammer
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
LT3021852T (lt) Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
BR112016010669A2 (pt) composição desinfetante
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
GT201400001S (es) Diseño de moto-bicicleta
DK3600363T3 (da) Sammensætninger omfattende bakteriestammer
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
KR102535561B9 (ko) 태양 전지를 이용한 구조물
GT201500018S (es) Diseño de motocicleta
GT201500015S (es) Diseño de motocicleta
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
DK3638271T3 (da) Sammensætninger omfattende bakteriestammer
GT201400068S (es) Configuracion aplicada a soporte de muebles
MX2017000862A (es) Formulacion de factor viii.
CL2016001370A1 (es) Formulaciones de biomasa

Legal Events

Date Code Title Description
FG Grant or registration